Recent patents on inflammation & allergy drug discovery最新文献

{"title":"Mechanisms of Hypersensitivity","authors":"B. Baldo, N. Pham","doi":"10.1007/978-3-030-51740-3_3","DOIUrl":"https://doi.org/10.1007/978-3-030-51740-3_3","url":null,"abstract":"","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"1991 1","pages":"59 - 137"},"PeriodicalIF":4.2,"publicationDate":"2020-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90382519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-Lactam Antibiotics","authors":"B. Baldo, N. Pham","doi":"10.1007/978-1-4614-7261-2_5","DOIUrl":"https://doi.org/10.1007/978-1-4614-7261-2_5","url":null,"abstract":"","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"24 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2020-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81501086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drugs and Other Agents Used in Anesthesia and Surgery","authors":"B. Baldo, N. Pham","doi":"10.1007/978-1-4614-7261-2_7","DOIUrl":"https://doi.org/10.1007/978-1-4614-7261-2_7","url":null,"abstract":"","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2020-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77686644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Pump Inhibitors","authors":"B. Baldo, N. Pham","doi":"10.1007/978-1-4614-7261-2_14","DOIUrl":"https://doi.org/10.1007/978-1-4614-7261-2_14","url":null,"abstract":"","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"438 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2020-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77036760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meet Our Editorial Board Member","authors":"K. Hon","doi":"10.2174/1872213x1401200309093832","DOIUrl":"https://doi.org/10.2174/1872213x1401200309093832","url":null,"abstract":"","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2020-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45395828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal Stem Cell-Mediated Immuno-Modulatory and Anti- Inflammatory Mechanisms in Immune and Allergic Disorders.","authors":"Mudasir B Gugjoo,&nbsp;Shahid Hussain,&nbsp;Amarpal,&nbsp;Riaz A Shah,&nbsp;Kuldeep Dhama","doi":"10.2174/1872213X14666200130100236","DOIUrl":"https://doi.org/10.2174/1872213X14666200130100236","url":null,"abstract":"<p><strong>Background: </strong>Mesenchymal Stem Cells (MSCs) are present in almost all the tissues of the body and act as the backbone of the internal tissue homeostasis. Among their various characteristic features, immuno-modulatory and/ anti-inflammatory properties play an important role in therapeutics.</p><p><strong>Objective: </strong>The current topic focuses on the characterization and immuno-modulatory and/ antiinflammatory properties of MSCs. To present and discuss the current status of MSCs immunomodulatory properties.</p><p><strong>Methods: </strong>Available literature on MSCs properties and patents have been detailed, critically interpreted, and discussed based upon available literature. The main focus has been on their characteristic immunomodulatory and anti-inflammatory properties though some of the basic characterization markers have also been detailed. The databases searched for the literature include PubMed, Med Line, PubMed Central, Science Direct and a few other scientific databases.</p><p><strong>Results: </strong>MSCs are present in a very limited concentration in the tissues, and as such their culture expansion becomes imperative. MSCs immuno-modulatory and anti-inflammatory roles are achieved through direct cell-cell contact and / by the release of certain factors. Such properties are controlled by micro-environment upon which currently very limited control can be exerted. Besides, further insights in the xeno-protein free culture media as against the fetal bovine serum is required.</p><p><strong>Conclusion: </strong>MSCs have been well-isolated, cultured and characterized from numerous tissues of the body. The majority of the studies have shown MSCs as immuno-compromised with immunomodulatory and / or anti-inflammatory properties except some of the latest studies that have failed to achieve the desired results and thus, demand further research. Further research is required in the area to translate the results into clinical application.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 1","pages":"3-14"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213X14666200130100236","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37593538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents.","authors":"Cheuk C Au,&nbsp;Kam L Hon,&nbsp;Alexander K C Leung,&nbsp;Alcy R Torres","doi":"10.2174/1872213X14999201124195724","DOIUrl":"https://doi.org/10.2174/1872213X14999201124195724","url":null,"abstract":"<p><strong>Background: </strong>Infectious encephalitis is a serious and challenging condition to manage. This overview summarizes the current literature regarding the etiology, clinical manifestations, diagnosis, management, and recent patents of acute childhood infectious encephalitis.</p><p><strong>Methods: </strong>We used PubMed Clinical Queries as a search engine and used keywords of \"encephalitis\" AND \"childhood\" Patents were searched using the key term \"encephalitis\" in google.patents.- com and patentsonline.com.</p><p><strong>Results: </strong>Viral encephalitis is the most common cause of acute infectious encephalitis in children. In young children, the clinical manifestations can be non-specific. Provision of empiric antimicrobial therapy until a specific infectious organism has been identified, which in most cases includes acyclovir, is the cornerstone of therapy. Advanced investigation tools, including nucleic acid-based test panel and metagenomic next-generation sequencing, improve the diagnostic yield of identifying an infectious organism. Supportive therapy includes adequate airway and oxygenation, fluid and electrolyte balance, cerebral perfusion pressure support, and seizure control. Recent patents are related to the diagnosis, treatment, and prevention of acute infectious encephalitis.</p><p><strong>Conclusion: </strong>Viral encephalitis is the most common cause of acute infectious encephalitis in children and is associated with significant morbidity. Recent advances in understanding the genetic basis and immunological correlation of infectious encephalitis may improve treatment. Third-tier diagnostic tests may be incorporated into clinical practice. Treatment is targeted at the infectious process but remains mostly supportive. However, specific antimicrobial agents and vaccines development is ongoing.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 2","pages":"156-165"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38643897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scenario of the Treatment of Arthritis with Natural Products.","authors":"Fernanda C M Gallotti,&nbsp;Mairim R Serafini,&nbsp;Sara M Thomazzi","doi":"10.2174/1872213X14666200228103001","DOIUrl":"https://doi.org/10.2174/1872213X14666200228103001","url":null,"abstract":"<p><strong>Background: </strong>Conventional treatments of arthritis use toxic and poorly tolerated drugs. Therefore, natural products are an alternative because they are important sources of bioactive substances with therapeutic potential.</p><p><strong>Objective: </strong>To perform synthesis of patent applications associated with the use of natural products in the technological development of the invention for use in treating arthritis.</p><p><strong>Methods: </strong>The search for patents was conducted using the following databases of World Intellectual Property Organization (WIPO), European Patent Office (EPO, Espacenet), United States Patents and Trademark Office (USPTO) and National Institute of Intellectual Property (INPI) using as keywords - arthritis, treatment and the International Patent Classification (IPC) A61K36 / 00.</p><p><strong>Results: </strong>A total of 617 patents related to the subject were registered in the period available in patents databases during the study period from the years 2005 to 2017, of which 44 were analyzed based on the established inclusion criteria. The most important countries for protecting these inventions were China, followed by the United States of America, the Republic of Korea and Japan. As for the typology of depositors, that were identified by Educational Institutions and Public Institutes of Research (IEIPP) and Companies and Private Research Institutes (EIPP).</p><p><strong>Conclusion: </strong>The analysis of patents made it possible to characterize the natural products used in the treatment of arthritis, with emphasis on botanical extracts (71%), as a single component, as well as in association with other botanical extracts, isolated compounds and minerals.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 2","pages":"95-105"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37684284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tinea Capitis: An Updated Review.","authors":"Alexander K C Leung,&nbsp;Kam L Hon,&nbsp;Kin F Leong,&nbsp;Benjamin Barankin,&nbsp;Joseph M Lam","doi":"10.2174/1872213X14666200106145624","DOIUrl":"https://doi.org/10.2174/1872213X14666200106145624","url":null,"abstract":"<p><strong>Background: </strong>Tinea capitis is a common and, at times, difficult to treat, fungal infection of the scalp.</p><p><strong>Objective: </strong>This article aimed to provide an update on the evaluation, diagnosis, and treatment of tinea capitis.</p><p><strong>Methods: </strong>A PubMed search was performed in Clinical Queries using the key term \"tinea capitis\". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. The information retrieved from the above search was used in the compilation of the present article. Patents were searched using the key term \"tinea capitis\" at www.freepatentsonline.com.</p><p><strong>Results: </strong>Tinea capitis is most often caused by Trichophyton tonsurans and Microsporum canis. The peak incidence is between 3 and 7 years of age. Non-inflammatory tinea capitis typically presents as fine scaling with single or multiple scaly patches of circular alopecia (grey patches); diffuse or patchy, fine, white, adherent scaling of the scalp resembling generalized dandruff with subtle hair loss; or single or multiple patches of well-demarcated area (s) of alopecia with fine-scale, studded with broken-off hairs at the scalp surface, resulting in the appearance of \"black dots\". Inflammatory variants of tinea capitis include kerion and favus. Dermoscopy is a highly sensitive tool for the diagnosis of tinea capitis. The diagnosis can be confirmed by direct microscopic examination with a potassium hydroxide wetmount preparation and fungal culture. It is desirable to have mycologic confirmation of tinea capitis before beginning a treatment regimen. Oral antifungal therapy (terbinafine, griseofulvin, itraconazole, and fluconazole) is considered the gold standard for tinea capitis. Recent patents related to the management of tinea capitis are also discussed.</p><p><strong>Conclusion: </strong>Tinea capitis requires systemic antifungal treatment. Although topical antifungal therapies have minimal adverse events, topical antifungal agents alone are not recommended for the treatment of tinea capitis because these agents do not penetrate the root of the hair follicles deep within the dermis. Topical antifungal therapy, however, can be used to reduce transmission of spores and can be used as adjuvant therapy to systemic antifungals. Combined therapy with topical and oral antifungals may increase the cure rate.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 1","pages":"58-68"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37515686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chitinases: Therapeutic Scaffolds for Allergy and Inflammation.","authors":"Kirtika Madan,&nbsp;Mansi Madan,&nbsp;Swapnil Sharma,&nbsp;Sarvesh Paliwal","doi":"10.2174/1872213X14666200114184054","DOIUrl":"https://doi.org/10.2174/1872213X14666200114184054","url":null,"abstract":"<p><strong>Background: </strong>Chitinases are the evolutionary conserved glycosidic enzymes that are characterized by their ability to cleave the naturally abundant polysaccharide chitin. The potential role of chitinases has been identified in the manifestation of various allergies and inflammatory diseases. In recent years, chitinases inhibitors are emerging as an alluring area of interest for the researchers and scientists and there is a dire need for the development of potential and safe chitinase antagonists for the prophylaxis and treatment of several diseases.</p><p><strong>Objective: </strong>The present review expedites the role of chitinases and their inhibitors in inflammation and related disorders.</p><p><strong>Methods: </strong>At first, an exhaustive survey of literature and various patents available related to chitinases were carried out. Useful information on chitinases and their inhibitor was gathered from the authentic scientific databases namely SCOPUS, EMBASE, PUBMED, GOOGLE SCHOLAR, MEDLINE, EMBASE, EBSCO, WEB OF SCIENCE, etc. This information was further analyzed and compiled up to prepare the framework of the review article. The search strategy was conducted by using queries with key terms \" chitin\", \"chitinase\", \"chitotrisidase\", \"acidic mammalian chitinase\", \"chitinase inhibitors\", \"asthma\" and \"chitinases associated inflammatory disorders\", etc. The patents were searched using the key terms \"chitinases and uses thereof\", \"chitinase inhibitors\", \"chitin-chitinase associated pathological disorders\" etc. from www.google.com/patents, www.freepatentsonline.com, and www.scopus.com.</p><p><strong>Results: </strong>The present review provides a vision for apprehending human chitinases and their participation in several diseases. The patents available also signify the extended role and effectiveness of chitinase inhibitors in the prevention and treatment of various diseases viz. asthma, acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer. In this regard, extensive pre-clinical and clinical investigations are required to develop some novel, potent and selective drug molecules for the treatment of various inflammatory diseases, allergies and cancers in the foreseeable future.</p><p><strong>Conclusion: </strong>In conclusion, chitinases can be used as potential biomarkers in prognosis and diagnosis of several inflammatory diseases and allergies and the design of novel chitinase inhibitors may act as key and rational scaffolds in designing some novel therapeutic agents in the treatment of variety of inflammatory diseases.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":"14 1","pages":"46-57"},"PeriodicalIF":4.2,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872213X14666200114184054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37539428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}